Abstract Number: PB0327
Meeting: ISTH 2022 Congress
Background: Thromboembolic events are life-threatening complication frequently observed in patients with heparin-induced thrombocytopenia (HIT). The interplay of platelets (PLTs) and different actors of the adaptive and innate immune system are increasingly identified to cause a procoagulant state in HIT. However, the impact of antibody (Ab)-induced Fc-gamma-RIIA (FcγRIIA) mediated procoagulant PLTs and their role regarding thrombus formation in HIT remains elusive.
Aims: In this study, the ability of HIT Abs to induce procoagulant PLTs and their potential to propagate thrombus formation was investigated.
Methods: PLTs from healthy individuals were incubated with IgG fractions from well characterized HIT patients or healthy controls (HCs) in the presence of low or high dose heparin. Changes in the expression of CD62P (P-selectin) and phosphatidylserine (PS) were assessed using a flow-cytometric procoagulant PLT-assay. To investigate whether HIT Ab-induced procoagulant PLTs affect thrombus formation, an ex-vivo model of thrombosis was used under flow conditions.
Results: HIT IgG fractions induced significant increase in the formation of CD62P/PS positive procoagulant PLTs compared to buffer and HC IgG (38.87%±1.99 vs. 4.43%±3.25, p=0.001; and vs. 1.43%±0.83, p=0.050, respectively, Figure 1A). Of note, HIT IgG incubated PLTs reconstituted into autologous whole blood induced marked increase in thrombus formation on collagen whereas these changes were nearly absent in HCs (Figure 1B). Interestingly, and of potential therapeutic interest, Ab-induced procoagulant PLT formation as well as increased thrombus formation were significantly reduced in the presence of the prostacyclin derivate Iloprost, an elevator of PLTs’ intracellular cAMP (Figure 1A).
Conclusion(s): Findings of our study indicate that HIT Abs harbour the ability to induce procoagulant PLTs via PLT FcγRIIA mediated signalling pathways. The observation that Iloprost showed the potential to reduce the formation of procoagulant PLTs and most importantly inhibits thrombus formation indicates a potential therapeutic use.
To cite this abstract in AMA style:Zlamal J, Jaffal H, Singh A, Pelzl L, Weich K, Althaus K, Backchoul T. Antibody-induced procoagulant platelets cause increased thrombus formation in heparin-induced thrombocytopenia [abstract]. https://abstracts.isth.org/abstract/antibody-induced-procoagulant-platelets-cause-increased-thrombus-formation-in-heparin-induced-thrombocytopenia/. Accessed February 20, 2024.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/antibody-induced-procoagulant-platelets-cause-increased-thrombus-formation-in-heparin-induced-thrombocytopenia/